BUFFALO, N.Y. — A Buffalo biotech company is moving ahead with plans for a brain cancer immunotherapy vaccine after receiving fast track approvals from the FDA. MimiVax LLC, which spun off from ...

MimiVax receives fast-track designation for brain cancer therapy

The device is indicated for newly diagnosed glioblastoma.

FDA Grants Fast Track Designation for MimiVax’s SurVaxM

MimiVax LLC, which spun off from Roswell Park Comprehensive Cancer Center, has been developing its SurVaxM therapy for several years for treatment of glioblastoma. The fast-track designation from ...

MimiVax LLC, which spun off from Roswell Park Comprehensive Cancer Center, has been developing its SurVaxM therapy for several years for treatment of glioblastoma.

The FDA Fast Track Designation is “designated to facilitate the development and expedite the review of drugs to treat serious medical conditions and fulfill unmet medical need,” according to MimiVax. "The receipt of Fast Track Designation affirms the ...

FDA Grants Fast Track Designation to SurVaxM for Newly Diagnosed Glioblastoma

The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park. BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation ...

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park. BUFFALO, N.Y., Oct. 14 ...

Credit: Pornpak Khunatorn via Getty Images. The US Food and Drug Administration (FDA) has granted fast track designation to MimiVax’s SurVaxM vaccine for the treatment of newly diagnosed glioblastoma (nGBM). The FDA’s decision was based on results from ...

FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM

The US Food and Drug Administration (FDA) has granted fast track designation to MimiVax’s SurVaxM vaccine for the treatment of newly diagnosed glioblastoma (nGBM). The FDA’s decision was ...

MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process. Glioblastoma is a rare disease with great unmet ...

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation ...

MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process. Glioblastoma is a rare disease with great unmet medical need. SurVaxM was developed to bring a paradigm shift to a ...

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug ...

The leptomeningeal metastases market is expected to grow significantly owing to an increasing incident population, less competitive scenarios, novel treatment options, the development of new ...

Leptomeningeal Metastases Treatment Market to Register Immense Growth by 2032, Predicts DelveInsight

DelveInsight's Leptomeningeal Metastases Market Insights report includes a comprehensive understanding of current treatment

Johnson & Johnson, Takeda Pharmaceutical, Millennium Pharmaceuticals, MimiVAx, TG Therapeutics The report is structured into chapters, with an introductory executive summary providing historical ...

Proteasome Inhibitors Market Size, A Forecasted Outlook for 2023-2030

SurVaxM is under clinical development by MimiVax and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

SurVaxM by MimiVax for High-Grade Glioma: Likelihood of Approval

SurVaxM is under clinical development by MimiVax and currently in Phase I for Medulloblastoma. According to GlobalData, Phase I drugs for Medulloblastoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

SurVaxM by MimiVax for Medulloblastoma: Likelihood of Approval

SurVaxM is under clinical development by MimiVax and currently in Phase I for Ependymoma. According to GlobalData, Phase I drugs for Ependymoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses ...

SurVaxM by MimiVax for Ependymoma: Likelihood of Approval

Ofranergene obadenovec (VB-111) from VBL Therapeutics is a targeted gene-therapy agent. SurVaxM by MimiVax is an immunotherapeutic vaccine that targets survivin. Vorasidenib (AG-881) by Servier is ...

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

SurVaxM is under clinical development by MimiVax and currently in Phase II for Brain Cancer. According to GlobalData, Phase II drugs for Brain Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData ...

SurVaxM by MimiVax for Brain Cancer: Likelihood of Approval

SurVaxM is under clinical development by MimiVax and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase I drugs for Oligodendroglioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

SurVaxM by MimiVax for Oligodendroglioma: Likelihood of Approval

MimiVax

Startups from all over the world were nominated, from North America to East Asia. In total, 44,000 startups were nominated in over 4,500 cities.

Meet the Winners of Startups in North and Central America

At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients.

MIMIVAX

mimivax.com

3 emps

Since 2012

MimiVax's stories on HackerNoon

Meet the Winners of Startups in North and Central America

MimiVax's latest news & mentions

MimiVax receives fast-track designation for brain cancer therapy

FDA Grants Fast Track Designation for MimiVax’s SurVaxM

MimiVax receives fast-track designation for brain cancer therapy

MimiVax receives fast-track designation for brain cancer therapy

FDA Grants Fast Track Designation to SurVaxM for Newly Diagnosed Glioblastoma

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM

FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

Leptomeningeal Metastases Treatment Market to Register Immense Growth by 2032, Predicts DelveInsight

Leptomeningeal Metastases Treatment Market to Register Immense Growth by 2032, Predicts DelveInsight

Proteasome Inhibitors Market Size, A Forecasted Outlook for 2023-2030

SurVaxM by MimiVax for High-Grade Glioma: Likelihood of Approval

SurVaxM by MimiVax for Medulloblastoma: Likelihood of Approval

SurVaxM by MimiVax for Ependymoma: Likelihood of Approval

SurVaxM by MimiVax for Medulloblastoma: Likelihood of Approval

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

SurVaxM by MimiVax for Brain Cancer: Likelihood of Approval

SurVaxM by MimiVax for Oligodendroglioma: Likelihood of Approval

Representing this company? Click here to claim and customize this page!

Reviews About MimiVax

MimiVax WIKI

Apply to get your Tech Company News Page live on HackerNoon.com today!

Light-Mode

Classic

Newspaper

Dark-Mode

Neon Noir

Minty

HN StartUps